Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Analysis of PD-L1, TMB, CTDNA in Immunotherapy Response Monitoring and Prediction in Advancer Lung Cancer Treatment.

NCT06227728 is registered in ClinicalTrials.gov with Gene Solutions as lead sponsor.

NCT NCT06227728
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06227728 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Analysis of PD-L1, TMB, CTDNA in Immunotherapy Response Monitoring and Prediction in Advancer Lung Cancer Treatment.
Lead sponsor
Gene Solutions
Phase
Observational
Overall status
Recruiting
Start date
March 22, 2024
Completion date
December 31, 2026
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, breast cancer, colorectal cancer, gastric cancer, immune checkpoint inhibitor, liver cancer, non small cell lung cancer